Ustur whole body case 0269: demonstrating effectiveness of i.v. CA-DTPA for Pu.
This whole body donation case (USTUR Registrant) involved a single acute inhalation of an acidic Pu(NO3)4 solution in the form of an aerosol 'mist'. Chelation treatment with intravenously (i.v.) Ca-EDTA was initiated on the day of the intake, and continued intermittently over 6 months. After 2.5 y with no further treatment, a course of i.v. Ca-DTPA was administered. A total of 400 measurements of 239+240Pu excreted in urine were recorded; starting on the first day (both before and during the initial Ca-EDTA chelation) and continuing for 37 y. This sampling included all intervals of chelation. In addition, 91 measurements of 239+240Pu-in-feces were recorded over this whole period. The Registrant died about 38 y after the intake, at age 79 y, with extensive carcinomatosis secondary to adenocarcinoma of the prostate gland. At autopsy, all major soft tissue organs were harvested for radiochemical analyses of their 238Pu, 239+240Pu and 241Am content. Also, all types of bone (comprising about half the skeleton) were harvested for radiochemical analyses, as well as samples of skin, subcutaneous fat and muscle. This comprehensive data set has been applied to derive 'chelation-enhanced' transfer rates in the ICRP Publication 67 plutonium biokinetic model, representing the behaviour of blood-borne and tissue-incorporated plutonium during intervals of therapy. The resulting model of the separate effects of i.v. Ca-EDTA and Ca-DTPA chelation shows that the therapy administered in this case succeeded in reducing substantially the long-term burden of plutonium in all body organs, except for the lungs. The calculated reductions in organ content at the time of death are approximately 40% for the liver, 60% for other soft tissues (muscle, skin, glands, etc.), 50% for the kidneys and 50% for the skeleton. Essentially, all of the substantial reduction in skeletal burden occurred in trabecular bone. This modelling exercise demonstrated that 3-y-delayed Ca-DTPA therapy was as effective as promptly administered Ca-EDTA.
James
A C
AC
US Transuranium and Uranium Registries, College of Pharmacy, Washington State University, 1845 Terminal Drive, Suite 201, Richland, WA 99354, USA. tjames@tricity.wsu.edu
Sasser
L B
LB
Stuit
D B
DB
Glover
S E
SE
Carbaugh
E H
EH
D001681:Biological Assay / Q000379:methods; D001822:Body Burden; D002614:Chelating Agents / Q000008:administration & dosage; D003198:Computer Simulation; D004334:Drug Administration Schedule; D006801:Humans; D008297:Male; D008954:Models, Biological; D004369:Pentetic Acid / Q000008:administration & dosage*; D011005:Plutonium / Q000493:pharmacokinetics* / Q000506:poisoning*; D011829:Radiation Dosage; D011832:Radiation Injuries / Q000209:etiology / Q000378:metabolism* / Q000517:prevention & control*; D011837:Radiation-Protective Agents / Q000008:administration & dosage; D011874:Radiometry / Q000379:methods*; D012062:Relative Biological Effectiveness; D015203:Reproducibility of Results; D012680:Sensitivity and Specificity; D016896:Treatment Outcome; D014915:Whole-Body Counting
D002614:Chelating Agents; D011837:Radiation-Protective Agents; D011005:Plutonium; D004369:Pentetic Acid